Depression News

The Biden-Harris Administration released the 2024 National Strategy for Suicide Prevention and Federal Action Plan, which includes actions to address substance use and suicide risk and evaluate community-based suicide prevention efforts.

Despite having improvements in pain and function, patients with self-reported anxiety or depression were more likely to be dissatisfied after total knee arthroplasty vs. patients without anxiety or depression, according to study results.

Air pollution accentuates the relationship between poor mental health and premature mortality from heart disease in the United States, researchers reported at ESC Preventive Cardiology 2024.

Arrivo Bio has dosed the first patient in a phase 2b clinical trial of SP-624, a novel SIRT6 activator being evaluated as a treatment for major depressive disorder, the company announced in a press release.

An 8-week prescription digital therapeutic for treatment of postpartum depression symptoms received FDA 510(k) clearance, according to a press release from Curio Digital Therapeutics.

DENVER — For those experiencing chronic migraine, the presence of self-reported psychiatric conditions did not affect the effectiveness of eptinezumab, according to a poster at the American Academy of Neurology annual meeting.

ATLANTA — Adults genetically predisposed to high stress are more likely to have a heart attack during times of heightened stress, such as a major holiday or after a presidential election, researchers reported.

Adults with strabismus were more likely to have mental health conditions, including anxiety, depression and substance use and addiction, compared with those without strabismus, according to a study published in JAMA Ophthalmology.

Targeted screening, integrated services and a biopsychosocial approach to care may help identify and manage anxiety and depression among people with vision loss, according to a perspective published in Psychodynamic Psychiatry.

Liafensine met all safety and efficacy endpoints and demonstrated significant improvements over placebo as a treatment for treatment-resistant depression in the phase 2b ENLIGHTEN trial, according to a manufacturer-issued press release.